Grail Inc reports results for the quarter ended June 30 - Earnings Summary
Grail Inc reports results for the quarter ended June 30 - Earnings Summary
Grail Inc GRAL.OQ reported a quarterly adjusted loss of $2.56 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.18. The mean expectation of nine analysts for the quarter was for a loss of $2.65 per share. Wall Street expected results to range from $-3.19 to $-2.20 per share.
Revenue rose 25.7% to $44.69 million from a year ago; analysts expected $42.76 million.
Grail Inc's reported EPS for the quarter was a loss of $2.56.
The company reported a quarterly loss of $110.25 million.
Grail Inc shares had risen by 6.5% this quarter and lost 15.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 5.4% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Grail Inc is $63.07, about 15.3% below its last closing price of $72.70
This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -2.65 | -2.56 | Beat |
Mar. 31 2026 | -2.76 | -2.29 | Beat |
Dec. 31 2025 | -2.71 | -2.44 | Beat |
Sep. 30 2025 | -3.52 | -2.46 | Beat |
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM